(ET-1) affects glucose uptake in adipocytes and may play an important role in adipose physiology. One of the principal functions of adipose tissue is the provision of energy substrate through lipolysis. In the present study, we investigated the effects of ET-1 on lipolysis in 3T3-L1 adipocytes. When glycerol release in the culture medium was measured as an index of lipolysis, the results showed that ET-1 caused a significant increase that was time and dose dependent. With a concentration of 10 nM ET-1, stimulation of glycerol release plateaued after 4 h of exposure. This effect was inhibited by the ETA receptor antagonist BQ-610 (10 M) but not by the ETB receptor antagonist BQ-788 (10 M). To further explore the underlying mechanisms of ET-1 action, we examined the involvement of the cAMPdependent protein kinase A-mediated, phospholipase A2 (PLA2)-mediated, protein kinase C (PKC)-mediated, phosphatidylinositol 3 (PI 3)-kinase-mediated, and the mitogen-activated protein kinase (MAPK)-mediated pathways. Inhibition of adenylyl cyclase activation by SQ-22536 (100 M) did not block ET-1-induced lipolysis. Pretreatment of adipocytes with the PLA2 inhibitor dexamethasone (100 nM), the PKC inhibitor H-7 (6 M), or the PI 3-kinase inhibitor wortmannin (100 nM) also had no effect. ET-1-induced lipolysis was blocked by inhibition of extracellular signal-regulated kinase (ERK) activation using PD-98059 (75 M), whereas a p38 MAPK inhibitor (SB-203580; 20 M) had no effect. Results of Western blot further demonstrated that ET-1 induced ERK phosphorylation. These data show that ET-1 induces lipolysis in 3T3-L1 adipocytes via a pathway that is different from the conventional cAMP-dependent pathway used by isoproterenol and that involves ERK activation.
levels (37) . Through these complex signaling systems, ET-1 evokes a diverse range of biological responses, including bronchoconstriction (13) , vasoconstriction (46) , cell proliferation (12, 26) , and modulation of hormone and neurotransmitter release (34, 48) .
Several lines of evidence suggest that ET-1 may play a role in the regulation of metabolic events. Elevated plasma ET-1 concentrations have been reported in a number of clinical disorders associated with insulin resistance, including diabetes and obesity (6, 39) . ET-1 levels were elevated in lean hypertensive subjects and were further increased in the presence of impaired glucose tolerance or hyperlipidemia (5) . Besides, hypertriglyceridemia and hyperinsulinemia have been suggested to be potent inducers of ET-1 release in humans (27) . Taken together, these observations suggest an association between ET-1 and metabolic disorders. Accumulated evidence has demonstrated the role of ET-1 in glucose metabolism; it is reported to regulate hepatic glycogenolysis (28) , glucose output (40) , and glucose uptake in several insulin target tissue, both in vitro (47, 45, 20) and in vivo (17, 24) . These findings suggest that ET-1 may play important roles in the regulation of metabolism.
Adipose tissues release energy in the form of free fatty acids (FFAs) through lipolysis of adipocyte triglyceride. Cellular lipolysis is usually estimated by measuring the end products, FFAs and glycerol, which are released in the incubation medium. Glycerol is commonly regarded as an indirect, but more accurate, index of the rate of lipolysis than FFA release, since glycerol, in contrast to FFA, is assumed not to be reutilized by adipocytes (1) . Several signaling pathways are involved in adipocyte lipolysis. The major pathway leading to lipolysis is the cAMP-dependent protein kinase A (PKA) pathway. Stimulation of G s -coupled receptors causes activation of adenylyl cyclase, and the subsequent increase in intracellular cAMP levels leads to the dissociation of PKA, the catalytic subunits of which then phosphorylate hormone-sensitive lipase (HSL). Phosphorylation of HSL increases its hydrolytic activity and the release of FFA and glycerol (14) . In addition, PKC activation induces adenylyl cyclase activity in rat adipocytes (22) . These results led us to speculate that PKC activation may cause lipolysis via adenylyl cyclase activation and subsequent cAMP elevation. Finally, there is evidence that increased FFA release from fat cells occurs after stimulation of the MAPK pathway (10) .
The role of ET-1 in glucose metabolism has been extensively investigated, but there have been very few studies on its role in lipid metabolism. The present study was designed to investigate the role of ET-1 in lipolysis and the underlying mechanism, using the 3T3-L1 adipocyte cell model. We first evaluated the effect of ET-1 on lipolysis by analyzing changes in the rate of glycerol release, determined which ET-1 receptor was involved using specific antagonists, and finally examined the signaling pathways leading to lipolysis using various inhibitors.
MATERIALS AND METHODS
Materials. ET-1 was purchased from the Peptide Institute (Osaka, Japan), BQ-610 and BQ-788 from Phoenix Pharmaceuticals (Belmont, CA), isobutylmethylxanthine, dexamethasone (Dex), insulin, and wortmannin (Wor) from Sigma (St. Louis, MO), and SQ-22536, H-7, PD-98059, and SB-203580 from Biomol International (Plymouth Meeting, PA).
Experimental design. To explore the effect of ET-1 on lipolysis, 3T3-L1 adipocytes were treated for different times (1-12 h) with a fixed concentration (10 nM) of ET-1 or with different concentrations (10 Ϫ11 to 10 Ϫ6 M) for a fixed time (4 h). Next, glycerol in the culture supernatant was measured colorimetrically using glycerol assay kits. To determine the receptor subtype(s) mediating ET-1-induced lipolysis, 3T3-L1 adipocytes were incubated for 1 h in the presence or absence of BQ-610 (an ET AR antagonist; 10 M) or BQ-788 (an ETBR antagonist; 10 M) and then incubated with 10 nM ET-1 in the continued presence or absence of the antagonist for a further 4 h. To gain an insight into the signaling pathway involved, the adipocytes were preincubated for 1 h in the presence or absence of various inhibitors acting on different signaling pathways and then incubated with 10 nM ET-1 in the continued presence or absence of these inhibitors for a further 4 h; the agents used were the adenylyl cyclase inhibitor SQ-22536 (100 M), the PLA 2 inhibitor Dex (100 nM), the PKC inhibitor H-7 (6 M), the PI 3-kinase inhibitor Wor (100 nM Cell culture. 3T3-L1 fibroblasts (American Type Culture Collection, Rockville, MD) were seeded on six-well plates (Falcon; BectonDickinson) and grown and maintained in Dulbecco's modified Eagle's (DME) high-glucose medium containing 100 U/ml penicillin, 100 g/ml streptomycin (all from GIBCO-BRL, Gaithersburg, MD), and 10% fetal bovine serum (complete medium; Biowest, Nuaillé, France) in 10% CO 2. The cells were grown to 2 days postconfluence and then induced to differentiate by incubation for 3 days in complete medium containing isobutylmethylxanthine (0.5 mM), Dex (0.5 M), and insulin (1.7 M; all from Sigma) and then in complete medium containing insulin for a further 3 days. The medium was then changed every 3 days until the cells were fully differentiated (21) . Typically, by day 10, Ͼ95% of the fibroblasts had differentiated into adipocytes, as determined by staining for lipid accumulation using Oil Red O (9). Before each experiment, cells were incubated for 6 h in the absence of serum using DME low-glucose medium containing 0.1% BSA. This study protocol was used in all experiments.
Glycerol measurement. Glycerol in culture supernatants was measured by a colorimetric method using glycerol assay kits (Randox Laboratories, Antrim, UK).
Western blot. Whole cell lysate was made by sonication in lysis buffer (1% Triton X-100, 50 mM KCl, 25 mM HEPES, pH 7.8, 10 g/ml leupeptin, 20 g/ml aprotinin, 125 M dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride). Samples (100 g total protein) in 50 l of Laemmli sample buffer were boiled for 10 min and resolved on 15% mini-SDS-PAGE. The contents of the gel were then transferred to a polyvinylidene difluoride membrane. The membrane was preblotted in 5% skimmed milk in PBS for 30 min at room temperature and immunoblotted with anti-phosphorylated and total ERK1/2 antibodies (Santa Cruz Biotechnology) for 24 h at 4°C. This was followed by horseradish peroxidase-conjugated secondary antibody for 60 min at room temperature and then by revelation with chemiluminescence reagent (Amersham Biosciences, Buckinghamshire, UK).
Statistical analysis. Experiments were repeated at least four times. The results are expressed as means Ϯ SD. Statistical significance was assessed by one-way ANOVA or Student's t-test, with a value of P Ͻ 0.05 being considered statistically significant.
RESULTS

ET-1 stimulates lipolysis in 3T3-L1 adipocytes.
Fully differentiated 3T3-L1 adipocytes were incubated with 10 nM ET-1 for various times, and the rate of glycerol release (expressed as glycerol release/h) was determined as a measure of the rate of lipolysis. As shown in Fig. 1A , a significant increase in lipolysis was seen in the ET-1-treated group after 1 h of incubation (47. , P Ͻ 0.05). This response was dose dependent, with an ED 50 of 1.82 nM. The maximal lipolysis seen in the presence of ET-1 was approximately fourfold higher than that in controls.
Effect of ET receptor antagonists on ET-1-induced lipolysis.
We then used the ET A R antagonist BQ-610 and the ET B R antagonist BQ-788 to examine the contribution of the two ET receptors to ET-1-induced lipolysis. 3T3-L1 adipocytes were pretreated with 1 M BQ-610 or 1 M BQ-788 for 1 h and then coincubated with inhibitor and 10 nM ET-1 for a further 4 h. BQ-610 or BQ-788 alone had no effect on basal lipolysis, but BQ-610 completely prevented ET-1-stimulated lipolysis while BQ-788 had no effect (Fig. 2) , demonstrating that the effect of ET-1 on lipolysis was mediated through the ET A R.
Effect of adenylyl cyclase inhibitor on ET-1-induced lipolysis.
As shown in Fig. 3 , treatment of the cells with isoproterenol (1 nM) caused a significant increase in glycerol release, and this effect was blocked by inhibition of adenylyl cyclase using SQ-22536 (100 M), showing that cAMP was the intracellular mediator for isoproterenol-induced lipolysis. In contrast, SQ-22536 pretreatment had no effect on ET-1-stimulated glycerol release, showing that ET-1-induced lipolysis did not involve the conventional cAMP-dependent pathway. Fig. 4 , pretreatment of 3T3-L1 adipocytes with inhibitors of PLA 2 ( Fig. 4A ; Dex, 100 nM), PKC ( Fig. 4B ; H-7, 6 M), or PI 3-kinase ( Fig. 4C ; Wor, 100 nM) had no effect on basal lipolysis or ET-1-induced lipolysis.
Effects of PLA 2 , PKC, or PI 3-kinase inhibitors on ET-1-induced lipolysis. As shown in
Effects of MAPK inhibitors on ET-1-induced lipolysis.
Pretreatment of 3T3-L1 adipocytes with the ERK inhibitor PD-98059 (75 M) completely blocked ET-1-induced lipolysis (P Ͻ 0.05), whereas the p38 inhibitor SB-203580 (20 M) had no effect (Fig. 5) , showing that ERK activation, but not p38 activation, was necessary for ET-1-stimulated lipolysis in 3T3-L1 adipocytes. To reduce the possibility of a nonspecific effect of high-dose PD-98059, two different concentrations of mitogen/extracellular signal-regulated kinase (MEK) inhibitors PD-98059 (10 and 75 M) and U-0126 (10 and 25 M) were used to clarify the involvement of the MAPK/ERK pathway in ET-1-induced lipolysis. Results indicated that pretreatment with low-dose PD-98059 (10 M) or U-0126 (10 M) can only partially inhibit ET-1-induced lipolysis (Fig. 6, A and B) . However, high-dose PD-98059 (75 M) or U-0126 (25 M) can fully inhibit ET-1-induced lipolysis (Fig. 6, A and B) . Fig. 4 . Effect of inhibitors of phospholipase A2 (PLA2), protein kinase C (PKC), and phosphatidylinositol 3-kinase (PI 3-kinase) on ET-1-induced lipolysis. Differentiated 3T3-L1 adipocytes were incubated in serum-free medium for 6 h, preincubated for 1 h in the absence or presence of the PLA2 inhibitor dexamethasone (A; Dex; 100 nM), the PKC inhibitor H-7 (B; 6 M), or the PI 3-kinase inhibitor wortmannin (C; Wor; 100 nM), and then incubated in the absence or presence of ET-1 (10 nM) in the continued absence or presence of the inhibitor for a further 4 h before the glycerol concentration in the medium was measured. The results are means Ϯ SD of triplicate measurements and are representative of those for four separate experiments. *P Ͻ 0.05 compared with vehicle control. 
DISCUSSION
The present study was performed to explore the metabolic role of ET-1 in lipolysis in 3T3-L1 adipocytes and to clarify the underlying signaling pathways. The main finding was that ET-1, acting via the ET A R, stimulated lipolysis in a timedependent and dose-dependent manner and by activation of the ERK pathway. As shown in Fig. 3 , an adenylyl cyclase inhibitor did not block ET-1-induced lipolysis, showing that the ET-1-mediated signaling pathway was different from the conventional pathway leading to lipolysis involving activation of cAMP-dependent PKA, which, in turn, activates other substrates, such as HSL and perilipin (14) . Several lines of evidence suggest that ET-1 has a dual effect on adenylyl cyclase activity. For example, ET-1 can stimulate adenylyl cyclase and cAMP generation in rat anterior pituitary, epididymal, and glomerular mesengial cells and cerebral slices (25, 36) , whereas it inhibits cAMP formation in brain capillary endothelial cells (19) and attenuates isoproterenol-induced accumulation of cAMP in smooth muscle cells (44) . These diverse effects of ET-1 on cAMP formation seem to be tissue specific. It is possible that ET receptors are coupled to different G proteins, such as G o , G q , G s , and G i . However, our data suggest that ET-1-stimulated lipolysis is cAMP-independent and that ET-1 does not activate adenylyl cyclase and increase cAMP formation in 3T3-L1 adipocytes. Guanylyl cyclase and cGMP has also been implicated in lipolysis induced by some lipolytic factors (32) . Whether ET-1-induced lipolysis involves a cGMP-dependent pathway is still unsettled.
Some studies have shown that, in smooth muscle cells, ET-1 stimulates PLA 2 activity and the release of arachidonic acid for prostaglandin synthesis (15, 41) , and there is evidence that prostaglandins may regulate or modulate lipolysis in adipocytes (3, 8) . It had been hypothesized that ET-1 could activate PLA 2 , increase prostaglandin synthesis, and thus cause lipolysis in 3T3-L1 adipocytes, but there was little evidence for this. In the present study, we used the PLA 2 inhibitor Dex (18) to clarify the role of PLA 2 in ET-1-induced lipolysis. As shown in Fig. 4A , pretreatment of cells with Dex to inhibit PLA 2 activation did not affect ET-1-induced lipolysis, indicating that the arachidonic acid cascade is not involved in ET-1-induced lipolysis.
In 3T3-L1 adipocytes, the binding of ET-1 to the ET A R may cause PI 3-kinase activation. For example, in 3T3-L1 adipocytes, ET-1, like insulin, stimulates glucose transport and GLUT4 translocation through a PI 3-kinase-dependent mechanism (16) , and PI 3-kinase is a key enzyme in the signaling of the insulin-mediated metabolic actions (33) . In rat adipocytes, the PI 3-kinase inhibitor Wor can completely abolish the ability of insulin to stimulate glucose uptake and its anti-lipolytic action (23) . In our study (Fig. 4B) , Wor did not prevent ET-1-induced lipolysis, showing that the underlying mechanism was not PI 3-kinase dependent.
Conventionally, hormonally stimulated lipolysis occurs by activation of cAMP-dependent PKA, which phosphorylates HSL and increases adipocyte lipolysis. In addition, there is evidence that G protein-coupled receptors can also activate MAPK pathways (11) . Three MAPK pathways have been identified, involving, specifically, the ERKs or one of the stress-activated protein kinases, JNKs or p38 MAPKs. ERKs are activated by growth factors acting via MAPK kinase kinases (e.g., Raf) and MAPK kinases (e.g., MEKs) and are involved in both cell proliferation and differentiation (2), whereas JNKs and p38 MAPKs are thought to be activated primarily in response to proinflammatory cytokines and environmental stress (2) . ␤-Adrenergic agonists can also activate ERKs in adipocytes (35) . Recent evidence suggests that catecholamines activate not only PKA, but also the ERK pathway, to regulate adipocyte lipolysis by phosphorylating HSL and increasing HSL activity (10) . In our study, we observed a significant phosphorylation of ERK (Fig. 7A ) in response to ET-1 treatment. The ERK inhibitors PD-98059 and U-0126 blocked ET-1-induced lipolysis (Figs. 5 and 6 ) and phosphorylation of ERK (Fig. 7B) , providing support for the role of ERK activation in the process of ET-1-induced lipolysis in adipocytes and also demonstrating the involvement of ERK activation in ET-1-induced lipolysis. HSL was previously considered to be an essential and possibly the only catalyst of adipose tissue lipolysis. On the contrary, the existence of HSL-independent lipolysis was also suggested from an experiment with a mouse model of HSL deficiency (7) . However, to date, the related data and underlying mechanisms of HSLindependent lipolysis still remain limited. Because the ET-1 lipolytic action is mediated by ERK activation, we postulated that ET-1-induced lipolysis may be also via increasing HSL activity. Given the above observations, we have hypothesized the following model for stimulation of lipolysis by ET-1 in 3T3-L1 adipocytes (Fig. 8) ; the binding of ET-1 to the ET A R leads to activation of the MAPK kinase kinase, Raf, which then phosphorylates and activates MEKs, which, in turn, phosphorylate and activate ERKs. Activated ERKs may then phosphorylate and activate HSL to cause subsequent lipolysis; however, the other unknown lipase may also be involved. The precise mechanism of ET-1-induced lipolysis needs further investigation.
In summary, the present study demonstrates that, in 3T3-L1 adipocytes, ET-1 induces cAMP-independent lipolysis via the ET A R and activation of the ERK pathway. In addition to its effects on glucose metabolism, our data demonstrated that ET-1 may play an important role in lipid metabolism. A previous study has shown that intraperitoneal injection of ET-1 significantly increases plasma FFA levels in pygmy goats (29) , and a recent study has shown that chronic ET-1 infusion causes a significant increase in plasma FFA levels in rats (43) . These observations all indicate that ET-1 has metabolic effects. Our study directly explored the role of ET-1 in lipid metabolism and found that ET-1 induces lipolysis in 3T3-L1 adipocytes. The interpretation of the findings presented here is that, in addition to ET-1 effects on glucose metabolism, ET-1 stimulation of lipolysis indicated that an endothelial-adipose interaction may also involve lipid metabolism, at least the lipolysis. Endothelial dysfunction and dyslipidemia are two major components characterizing several metabolic disorders, e.g., obesity-, insulin resistance-, or diabetes-associated hypertension. Dysregulation of the endothelial system results in elevated ET-1 concentrations and may subsequently contribute to the vigorous lipolysis under various pathological statuses. Further studies are required to clarify its role in lipid metabolism and in the pathogenesis of metabolic disorders, such as insulin resistance and obesity.
